Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers
US10183939B2 · kind B2 · utility
36Cited by
1References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 11, 2015 |
| Grant date | Jan 22, 2019 |
| Priority date | — |
| Expiry date | Sep 11, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D405/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to novel compounds. The compounds of the invention are kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Raf kinases, e.g., B-Raf and C-Raf. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Raf kinases, for example, cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.